Samsrita Labs (BSE 539267)₹11.74−1.10%Healthcare Service Provider
In the Jun 2026 quarter (consolidated), Samsrita Labs reported sales of ₹0 Cr and net profit of −₹0.18 Cr. For the year to Mar 2026, sales were ₹0.03 Cr and net profit −₹8.13 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.03 | 0.00 |
| Expenses | 4.94 | 3.37 | 0.18 | 0.32 |
| Operating Profit | −4.94 | −3.37 | −0.16 | −0.32 |
| OPM % | — | — | −749.9% | — |
| Other Income | 0.00 | 0.00 | 0.04 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | −4.92 | −3.35 | −0.11 | −0.30 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit | −4.53 | −2.93 | −0.47 | −0.18 |
| EPS (Rs) | −1.99 | −1.28 | −0.20 | −0.07 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.29 | 0.59 | 1.91 | 1.44 | 0.02 | 0.03 | 0.03 | 0.00 | 0.00 | 0.03 | 0.03 |
| Expenses | 1.87 | 1.72 | 4.35 | 3.63 | 0.93 | 0.44 | 1.02 | 0.26 | 0.27 | 8.76 | 8.81 |
| Operating Profit | −0.59 | −1.14 | −2.45 | −2.20 | −0.92 | −0.42 | −1.00 | −0.26 | −0.27 | −8.74 | −8.79 |
| OPM % | −45.2% | −194.7% | −128.4% | −153.1% | −9,100.0% | −2,049.9% | −4,949.9% | — | — | −43,549.9% | −29,300.0% |
| Other Income | 0.02 | 0.04 | 0.12 | 0.17 | 0.16 | 1.92 | 0.30 | 0.00 | 0.00 | 0.04 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | −0.57 | −1.10 | −2.35 | −2.05 | −0.76 | 1.48 | −0.69 | −0.24 | −0.25 | −8.66 | −8.68 |
| Tax % | 124.2% | −5.4% | −1.3% | −3.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Net Profit | −1.30 | −1.04 | −2.32 | −1.97 | −0.76 | 1.48 | −0.70 | −0.25 | −0.27 | −8.13 | −8.11 |
| EPS (Rs) | −1.27 | −0.88 | −1.68 | −1.33 | −0.51 | 1.00 | −0.47 | −0.17 | −0.18 | −3.58 | −3.54 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.25 | 11.73 | 13.78 | 14.78 | 14.79 | 14.80 | 14.80 | 14.78 | 14.78 | 22.71 |
| Reserves | −2.38 | −0.39 | −1.60 | −3.02 | −3.65 | −1.57 | −2.28 | −2.54 | −2.83 | −10.98 |
| Borrowings | 6.49 | 6.80 | 7.91 | 8.57 | 2.33 | 2.73 | 2.07 | 2.21 | 2.42 | 1.65 |
| Other Liabilities | 4.87 | 4.74 | 6.11 | 7.85 | 3.11 | 1.17 | 0.97 | 1.10 | 1.17 | 0.99 |
| Total Liabilities | 19.23 | 22.88 | 26.20 | 28.18 | 16.58 | 17.13 | 15.56 | 15.55 | 15.54 | 14.37 |
| Fixed Assets | 0.47 | 0.37 | 0.27 | 0.14 | 0.03 | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 |
| CWIP | 14.84 | 16.12 | 17.75 | 18.97 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 1.99 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 4.21 | 4.79 | 4.79 | 4.78 | 4.75 | 9.82 |
| Other Assets | 3.92 | 6.39 | 8.18 | 9.07 | 9.09 | 9.07 | 7.50 | 7.50 | 7.54 | 2.56 |
| Inventories | 0.00 | 0.09 | 0.15 | 0.12 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Trade receivables | 3.26 | 2.86 | 2.20 | 2.17 | 2.13 | 2.11 | 2.09 | 2.08 | 2.08 | 0.01 |
| Cash & equivalents | 0.02 | 0.33 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.62 |
| Total Assets | 19.23 | 22.88 | 26.20 | 28.18 | 16.58 | 17.13 | 15.56 | 15.55 | 15.54 | 14.37 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −0.27 | −3.33 | −2.97 | −1.06 | −0.35 | −0.41 | 0.67 | −0.14 | −0.24 | −4.27 |
| Cash from investing activity | −1.10 | −1.20 | −1.56 | −1.12 | −0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27 |
| Cash from financing activity | 1.28 | 4.84 | 4.20 | 2.18 | 0.56 | 0.41 | −0.68 | 0.14 | 0.23 | 2.64 |
| Net cash flow | −0.07 | 0.31 | −0.31 | 0.00 | −0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.62 |
| Capex | 0.00 | 1.20 | 1.56 | 1.12 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free cash flow | −0.25 | −4.50 | −4.50 | −2.15 | −0.56 | −0.39 | 0.65 | −0.12 | −0.22 | −0.99 |
| CFO / OP % | 45.0% | 294.1% | 121.1% | 48.1% | 37.1% | 98.1% | −66.9% | 52.1% | 88.0% | 49.1% |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 932 | 1,806 | 425 | 556 | 78,110 | 38,690 | 38,325 | — | — | 365 |
| Inventory days | 0 | — | — | — | — | 0 | 0 | — | — | 0 |
| Cash conversion cycle | 933 | 1,807 | 426 | 557 | 78,111 | 38,691 | 38,326 | — | — | 366 |
| Working capital days | −1,115 | −2,259 | −788 | −1,463 | 60,590 | 58,765 | 46,172 | — | — | −29,748 |
| ROCE % | — | −5.5% | −10.2% | −8.5% | −4.1% | 10.1% | −4.6% | −1.7% | −1.8% | −62.5% |
For the Jun 2026 quarter, Samsrita Labs reported sales of ₹0 Cr and net profit of −₹0.18 Cr.
Samsrita Labs' sales for the year to Mar 2026 were ₹0.03 Cr; over the last twelve months they were ₹0.03 Cr.
Net profit for the year to Mar 2026 was −₹8.13 Cr, and −₹8.11 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−3.54.
Samsrita Labs reported borrowings of ₹1.65 Cr at Mar 2026, against cash and equivalents of ₹1.62 Cr.
Cash from operations was −₹4.27 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹0.99 Cr.